Tilray receives authorization to distribute MMJ in Italy

Tilray Medical has announced the introduction of three new medical cannabis flower varieties in Italy. Through its wholly-owned subsidiary, FL Group, Tilray has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use.

Starting this month, several Tilray Medical products have been approved for therapeutic use in Italy and are now available for distribution through pharmacies nationwide. These products include Tilray THC 25%, Tilray THC 18%, and Tilray THC 9% / CBD 9%.

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, stated, "This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being. We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care. We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing healthcare and patient wellness through innovation and collaboration."